Pure Global AI
NCT06410131Not yet recruiting

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL008.16, a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody, in Patients With Advanced or Metastatic Solid Tumors
Sound Biopharmaceuticals Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
FTL008.16
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sound Biopharmaceuticals Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
May 01, 2027
Enrollment
68 participants
Primary outcome

Number of participants with dose-limiting toxicities (DLTs)

Summary

This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate
 safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with
 advanced and metastatic solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410131
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410131 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sound Biopharmaceuticals Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 68 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.